Tacrolimus and mycophenolate mofetil regimens in transplantation: Benefits and pitfalls

BioDrugs

Volumn 11, Issue 6, 1999, Pages 395-407

  Ciancio, Gaetano ^a   Burke, George W ^a   Roth, David ^a   Miller, Joshua ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS;

ADULT; CADAVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERANCE; FOLLOW UP; GRAFT REJECTION; HEADACHE; HUMAN; IMMUNE FUNCTION TEST; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; INTESTINE TRANSPLANTATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PANCREAS TRANSPLANTATION; PARESTHESIA; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; TREMOR;

EID: 0032981286     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199911060-00004     Document Type: Review

References (65)

1. 1. Starzl TE, Todo S, Fung J, et al. FK506 for liver, kidney, and pancreas transplantation. Lancet 1989; 11: 1000-4
2. 2. Allison AC, Almquist SJ, Muller CD, et al. In vitro immunosuppressive effects of mycophenolic acid and ester pro-drug, RS-61443. Transplant Proc 1991; 23: 10-4
3. 3. Sollinger HW, Deierhoi MH, Belzer FO, et al. RS-61443 a phase I clinical trial and pilot rescue study. Transplantation 1992; 53: 428-32
4. 4. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitru. J Antibiot 1987; 40: 1256-65
5. 5. Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of Cyclopsorin A and FK506. Clin Immunol Immunopathol 1996; 80: S40-5
6. 6. Sawada S, Suzuki GEN, Kawase Y, et al. Novel immunosuppressive agent, FK506: in vitro effects on cloned T cell activation. J Immunol 1987; 139: 1797-803
7. 7. Ciancio G, Roth D, Burke G, et al. Renal transplantation in a new immunosuppressive era. Transplant Proc 1995; 27: 812-3
8. 8. Ciancio G, Rosen A, Loreto-Grand B, et al. The current advantage of FK506 in cadaver kidney transplantation. Transplant Proc 1996; 28: 1000-1
9. 9. Wagner K, Herget S, Heemann U. Experimental and clinical experience with the use of tacrolimus (FK506) in kidney transplantation. Clin Nephrol 1996; 45: 332-5
10. 10. Shapiro R, Jordan ML, Scantlebury VP, et al. Tacrolimus in renal transplantation. Transplant Proc 1996; 28: 2117-8
11. 11. Tzakis A, Webb M, Nery J, et al. Experience with intestinal transplantation at the University of Miami. Transplant Proc 1996; 28: 2748-9
12. 12. Burke GW, Alejandro R, Ciancio G, et al. The use of FK506 in simultaneous pancreas/kidney transplantation: rescue, induction, and maintenance immunosuppression. Transplant Proc 1995; 27: 3123-4
13. 13. Pham SM, Kormos RL, Hattler BG, et al. A prospective trial of tacrolimus (FK506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovas Surg 1996; 111: 764-72
14. 14. Keenan RJ, Konishi H, Kawai A, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995; 60: 580-4
15. 15. Przepiorka D, Ippoliti I, Woo M, et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996; 88: 4383-9
16. 16. Woodle ES, Thistlethwaite R, Gordon JH, et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. Transplantation 1996; 62: 594-9
17. 17. Vicenti F, Laskow DA, Neylan JF, et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U. S. Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 61: 1576-81
18. 18. Pirsh JD. Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63; 977-83
19. 19. Roth D, Colona J, Burke G, et al. Primary therapy with FK506 (FK) in kidney transplantation. Proceedings of the American Society of Transplant Physicians [abstract]. 15th Annual Meeting of the American Society of Transplant Physicians 1996 May; Chicago (IL); 264: 150
20. 20. Sollinger HW, Knechtle SJ, Reed A, et al. Experience with 100 consecutive simultaneous kidney-pancreas transplants with bladder drainage. Ann Surg 1991; 214: 703-11
21. 21. Hariharan S, Munda R, Cavallo T, et al. Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. Transplantation 1996; 61: 1161-5
22. 22. Stratta RJ, Taylor RJ, Castaldo P, et al. FK506 induction and rescue therapy in pancreas transplant recipients. Transplant Proc 1996; 28: 991-2
23. 23. Alloway RR, Russell WC, Gaher LW, et al. Conversion from cyclosporine to laerolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience. Transplant Proc 1996; 28: 995-7
24. 24. Gruessner RWG, Burke G, Stratta R, et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996; 61: 261-73
25. 25. Xenos ES, Ciancio G, Burke GW, et al. The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60. Clin Transpl 1997; 11: 497-9
26. 26. Ciancio G, Burke G, Ruth D, et al. Use of intravenous FK506 to treat acute rejection in simultaneous pancreas-kidney transplant recipients on maintenance oaul FK506. Transplantation 1997; 63: 785-8
27. 27. Ciancio G, Siquijor AP, Burke GW, et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. Clin Transpl 1997; 11: 243-9
28. 28. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990; 23: 1767-9
29. 29. Groth CG, Ohlman S, Gannedahl G, et al. New immunosuppressive drugs in transplantation. Transplant Proc 1993; 25: 2681-3
30. 30. Deierhoi MH, Kauffman RS, Hudson SL, et al. Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single centre. Ann Surg 1993; 217: 476-84
31. 31. Sollinger HW, Belzer FO, Deierhoi MH, et al. RS-61443 (Mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection. Ann Surg 1992; 216: 513-9
32. 32. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A Minded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-37
33. 33. Solliger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-32
34. 34. Klupp J, Bechstein WO, Platz KP, et al. Mycophenolate mofetil added to immunosuppression after liver transplantation: First results. Transplant Int 1997; 10: 223-8
35. 35. Klintmalm GB, Asher NL, Busuttil RW, et al. RS-61443 for treatment-resistant human liver rejection. Transplant Proc 1993; 25: 697
36. 36. Gavlik, Golberg MG, Tsarouchan A, et al. Mycophenolate mofetil rescue therapy in liver transplant recipients. Transplant Proc 1997; 29: 549-52
37. 37. Freise CE, Herbet M, Osorio RW, et al. Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation. Transplant Proc 1993; 25: 1758-9
38. 38. McDiarmid SV. Mycophenolate mofetil in liver transplantation. Clin Transpl 1996; 10: 140-5
39. 39. Garcia-Morales R, Carreno M, Mathew J, et al. The effects of chimeric cells following donor bone marrow infusions as detected by PCR-Flow assays in kidney transplant recipients. J Clin Invest 1997; 99: 1118-29
40. 40. Roth D, Colona J, Burke GW, et al. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation 1998, 65: 248-52
41. 41. Mendez R, for the FK506 MMF Dose-Ranging Kidney Transplant Study Group. FK506 and mycophenolate mofetil in renal transplant recipients: six-months results of a multicenter, randomized dose ranging trial. Transplant Proc 1998; 30: 1287-9
42. 42. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of Tacrolimus/Prednisone versus Tacrolimus/ Prednisone/Mycophenolate Mofetil in cadaveric renal transplantation-first report [abstract # 293]. Program and Abstracts of the 16th Annual Scientific Meeting ofthe American Society of Transplant Physicians; 1997 May; Chicago (IL)
43. 43. Zucker K, Rosen A, Tsuroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant recipients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol 1997; 5: 225-32
44. 44. Weppler D, Khan R, Fragulidis GP, et al. Status of liver and gastrointestinal transplantation at the University of Miami. In: JM Cecka, PI Terasaki, editors. Clinical Transplants 1996. Los Angeles: UCLA Tissue Typing Laboratory; 1996; 14: 187-201
45. 45. Karatzas T, Khan F, Tzakis AG. Clinical intestinal transplantation: experience in Miami. Transplant Proc 1997; 29: 1787-9
46. 46. Regazzi MB, Alessiani M, Reggiani P, et al. Pharmacokinetics of FK506 and mycophenolic acid in experimental and clinical intestinal transplantation. Transplant Proc 1997; 29: 1857-60
47. 47. Iacona I, Alessiani M, Spada M, et al. Mycophenolic acid in combination with FK506: a pharmacokinetic study in piglets after small-bowel transplantation. Transplant Proc 1997; 29: 701-2
48. 48. Alessiani M, Spada M, Costa A, et al. Morphological and functional changes in small-bowel allografts of pigs under combined tacrolimus and mycophenolate mofetil immunosuppression. Transplant Proc 1997; 29: 691-2
49. 49. Tzakis AG, Nery JR, Thompson A, et al. New immunosuppression regimens in clinical intestinal transplantation. Transplant Proc 1997; 29: 683-5
50. 50. Stratta RJ. Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multicenter report: the FK/MMF Multi-Centre Study Group. Transplant Proc 1997; 29: 654-5
51. 51. Burke GW, Ciancio G, Garcia-Morales R, et al. Evidence for microchimerism in peripheral blood, bone marrow and skin following donor bone marrow/kidney-pancreas transplantation at 3 years. Transplant Proc 1998; 30: 1555
52. 52. Burke GW, Ricordi C, Karatzas T, et al. Donor bone marrow infusion in simultaneous pancreas/kidney transplantation with OKT3 induction: Evidence for augmentation of chimerism. Transplant Proc 1997; 29: 1207-8
53. 53. Burke GW, Ciancio G, Alejandro R, et al. Use of tacrolimus and mycophenolate mofetil for pancreas kidney transplantation with or without OKT3 induction. Transplant Proc 1998; 30: 1544-5
54. 54. Ciancio G, Burke G, Levi D, et al. Simultaneous pancreas/kidney transplantation without antibody therapy induction. J Urol 1998; 709A: 159
55. 55. Ciancio G, Burke G, Viciana A, et al. Use of intravenous tacrolimus to reverse vascular rejection in kidney and simultaneous kidney-pancreas transplantation. Transplant Proc 1998; 30: 1536-7
56. 56. Garcia-Morales R, Esquenazi V, Zucker K, et al. Assessment of the effects of cadaveric donor bone marrow on chimerism kidney transplant recipients by the polymerase chain reaction-flow technique. Transplant Proc 1997; 29: 1219-21
57. 57. Garcia-Morales R, Esquenazi V, Carreno M, et al. PCR-flow analysis used to detect the levels of chimerism in peripheral blood of bone-marrow infused organ allograft recipients at the time of rejection episodes. Transplant Proc 1997; 29: 2179-80
58. 58. Ciancio G, Carreno M, Mathew J, et al. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK506 and OKT3 induction therapy. Transplant Proc 1996; 28: 943-4
59. 59. Garcia-Morales R, Carreno M, Mathew J, et al. Continuing observations on the regulatory effects of donor-specific bone marrow cell infusions and chimerism in kidney transplant recipients. Transplantation 1998; 65: 956-65
60. 60. Ciancio G, Garcia-Morales R, Burke GW, et al. Donor bone marrow, chimerism, histocompatibility and renal allograft rejection. Transplant Proc 1999; 31; 679
61. 61 Garcia-Morales R, Esquenazi V, Zucker K, et al. An assessment of the effects of cadaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometry. Transplantation 1996; 62: 1149-60
62. 62. Tanabe K, Koga S, Takahashi K, et al. Diabetes mellitus after renal transplantation under FK506 (tacrolimus) as primary immunosuppression. Transplant Proc 1996; 28: 1304-5
63. 63. Herget S, Heemann U, Friedrich J, et al. Initial experience with tacrolimus rescue therapy in OKT3 resistant rejection. Clin Nephrol 1996; 45: 352-4
64. 64. Eberkard O, Kliem V, Oldhafer K, et al. How best to use tacrolimus (FK506) for treatment of steroid and OKT3-resistant rejection after renal transplantation. Transplantation 1996; 61: 1345-9
65. 65. Jordan ML, Shapiro R, Naraghi R, et al. Tacrolimus rescue therapy for renal transplant rejection. Transplant Proc 1196; 28: 2119-20